Sec Form 13G Filing - Aisling Capital IV LP @ Viracta Therapeutics Inc.

Sec Form 13G Filing - Aisling Capital IV LP filing for Viracta Therapeutics Inc. (VIRX) - 2022-02-14

Insider filing report for Changes in Beneficial Ownership

Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. )*

Viracta Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

92765F108

(CUSIP Number)

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

Check the Appropriate Box to Designate the Rule Pursuant to Which this Schedule Is Filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(1)	Calculated based on 37,311,960 shares of Common Stock outstanding as of November 3, 2021 as reported on the Issuer’s Form 10-Q, filed on November 10, 2021.

(1)	Calculated based on 37,311,960 shares of Common Stock outstanding as of November 3, 2021 as reported on the Issuer’s Form 10-Q, filed on November 10, 2021.

(1)	Calculated based on 37,311,960 shares of Common Stock outstanding as of November 3, 2021 as reported on the Issuer’s Form 10-Q, filed on November 10, 2021.

(1)	Calculated based on 37,311,960 shares of Common Stock outstanding as of November 3, 2021 as reported on the Issuer’s Form 10-Q, filed on November 10, 2021.

(1)	Calculated based on 37,311,960 shares of Common Stock outstanding as of November 3, 2021 as reported on the Issuer’s Form 10-Q, filed on November 10, 2021..


Item 1(a).		Name of Issuer

		Viracta Therapeutics, Inc. (the “Issuer”)

Item 1(b).		Address of the Issuer’s Principal Executive Offices

		2533 S. Coast Hwy 101, Suite 210 Cardiff, CA 92007

Item 2(a).		Names of Persons Filing

		This statement is filed by the entities and persons listed below, all of whom together are referred to herein as the “Reporting Persons”: (i) Aisling Capital IV, LP (ii) Aisling Capital Partners IV LLC (iii) Aisling Capital Partners IV, LP (iv) Steve Elms (v) Andrew N. Schiff

Item 2(b).		Address of the Principal Business Office, or if none, Residence:

		C/O Aisling Capital Management LP 888 Seventh Ave., 12th Floor New York, NY 10106

Item 2(c).		Citizenship

		See responses to Item 4 on each cover page.

Item 2(d).		Title of Class of Securities

		Common Stock

Item 2(e).		CUSIP Number

		92765F108

Item 3.		If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a(n):

		Not Applicable.

Item 4.		Ownership

		(a) Amount beneficially owned: See responses to Item 9 on each cover page. (b) Percent of Class: See responses to Item 11 on each cover page. (c) Number of shares as to which the Reporting Person has: (i) Sole power to vote or to direct the vote: See responses to Item 5 on each cover page. (ii) Shared power to vote or to direct the vote: See responses to Item 6 on each cover page.


		(iii) Sole power to dispose or to direct the disposition of: See responses to Item 7 on each cover page. (iv) Shared power to dispose or to direct the disposition of: See responses to Item 8 on each cover page. The securities are directly held by Aisling Capital IV, LP (“Aisling”). Aisling Capital Partners IV, LP (“Aisling GP”), is the general partner of Aisling, and Aisling Capital Partners IV LLC (“Aisling Partners”), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms, who share v oting power and dispositive powers over securities held by Aisling, and as a result, may each be deemed to have beneficial ownership over such securities. This Statement shall not be construed as an admission that any of the Reporting Persons are, for purposes of Section 13(d) and 13(g), beneficial owners of the reported securities.

Item 5.		Ownership of Five Percent or Less of a Class

		As of the date of this Statement, each Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities.

Item 6.		Ownership of More than Five Percent on Behalf of Another Person

		Not Applicable.

Item 7.		Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

		Not Applicable.

Item 8.		Identification and Classification of Members of the Group

		Not Applicable.

Item 9.		Notice of Dissolution of Group

		Not Applicable.

Item 10.		Certification

		Not Applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2022


AISLING CAPITAL IV, LP By Aisling Capital Partners IV, LP, its General Partner By Aisling Capital Partners IV LLC, its General Partner

By:		/s/ Andrew Schiff
Name:		Andrew Schiff
Title:		Managing Member

EXHIBIT LIST

Exhibit A Joint Filing Agreement, dated as of February 14, 2022

Names of Reporting Persons

Aisling Capital IV, LP

Check The Appropriate Box if a Member of a Group (See Instructions)

(a) ☐ (b) ☐

SEC Use Only

Citizenship or Place of Organization

Delaware